Similarly, against IL-5, reslizumab was able to reduce asthma exacerbations and OCS intake in treated patients; unlike other drugs, it was administered intravenously, which is a method that is yet to be approved in several countries [32,33,34,35,82]. Here, IL5 is linked to asthma.